Susanna Mandruzzato

List of Publications by Citations

Source: https://exaly.com/author-pdf/2733773/susanna-mandruzzato-publications-by-citations.pdf
Version: 2024-04-10

74 papers	7,383 citations	35 h-index	84 g-index
84 ext. papers	8,570 ext. citations	8.8 avg, IF	5.46 L-index

#	Paper	IF	Citations
74	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nature Communications*, **2016**, 7, 12150	17.4	1388
73	Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. *Immunity*, **2010**, 32, 790-802	32.3	644
72	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. *Nature Medicine*, **2012**, 18, 1254-61	50.5	636
71	Myeloid-derived suppressor cell heterogeneity and subset definition. *Current Opinion in Immunology*, **2010**, 22, 238-44	7.8	520
70	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. *Journal of Clinical Investigation*, **2015**, 125, 3365-76	15.9	351
69	A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. *Journal of Experimental Medicine*, **1997**, 186, 785-93	16.6	284
68	Myeloid-derived suppressor cell heterogeneity in human cancers. *Annals of the New York Academy of Sciences*, **2014**, 1319, 47-65	6.5	280
67	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. *Blood*, **2011**, 118, 2254-65	2.2	280
66	IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. *Journal of Immunology*, **2009**, 182, 6562-8	5.3	263
65	Part I: Vaccines for solid tumours. *Lancet Oncology, The*, **2004**, 5, 681-9	21.7	180
64	Myeloid-derived suppressor cells in cancer patients: a clinical perspective. *Journal of Immunotherapy*, **2012**, 35, 107-15	5	176
63	Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. *Cell Reports* , **2012**, 2, 628-39	10.6	152
62	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. *Cancer Immunology, Immunotherapy*, **2016**, 65, 161-9	7.4	140
61	Identification of genes selectively regulated by IFNs in endothelial cells. *Journal of Immunology*, **2007**, 178, 1122-35	5.3	123
60	Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. *BMC Genomics*, **2013**, 14, 589	4.5	120
59	Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. *Biomaterials*, **2016**, 96, 47-62	15.6	98
58	A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. *Immunogenetics*, **1996**, 43, 377-83	3.2	90

57	Complexity and challenges in defining myeloid-derived suppressor cells. *Cytometry Part B - Clinical Cytometry*, **2015**, 88, 77-91	3.4	86
56	Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. *Journal of Leukocyte Biology*, **2011**, 89, 721-7	6.5	86
55	Common cancer biomarkers. *Cancer Research*, **2006**, 66, 2953-61	10.1	84
54	Complexity and challenges in defining myeloid-derived suppressor cells. *Cytometry Part B - Clinical Cytometry*, **2014**,	3.4	82
53	A gene expression signature associated with survival in metastatic melanoma. *Journal of Translational Medicine*, **2006**, 4, 50	8.5	82
52	Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. *Oncotarget*, **2016**, 7, 1168-84	3.3	82
51	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 **2019**, 7, 255		81
50	Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. *European Journal of Immunology*, **2014**, 44, 3307-19	6.1	81
49	Antigen specificity of immune suppression by myeloid-derived suppressor cells. *Journal of Leukocyte Biology*, **2011**, 90, 31-6	6.5	67
48	The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion **2019**, 7, 58		57
47	Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. *International Journal of Cancer*, **2006**, 119, 1717-22	7.5	50
46	Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. *Oncotarget*, **2014**, 5, 6611-9	3.3	49
45	Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. *Cancer Research*, **2009**, 69, 9385-94	10.1	47
44	MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. *Cancer*, **2001**, 91, 1882-1888	6.4	42
43	Cancer vaccines: pessimism in check. *Nature Medicine*, **2004**, 10, 1278-9; author reply 1279-80	50.5	40
42	Melanoma-restricted genes. *Journal of Translational Medicine*, **2004**, 2, 34	8.5	40
41	Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. *Journal of Immunology*, **2002**, 169, 4017-24	5.3	36
40	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. *OncoImmunology*, **2016**, 5, e1249559	7.2	35

39	An integrative framework identifies alternative splicing events in colorectal cancer development. *Molecular Oncology*, **2014**, 8, 129-41	7.9	34
38	Myeloid cell diversification and complexity: an old concept with new turns in oncology. *Cancer and Metastasis Reviews*, **2011**, 30, 27-43	9.6	34
37	MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. *International Journal of Cancer*, **2001**, 93, 85-90	7.5	34
36	Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5Rtriphosphate. *Biochemical and Biophysical Research Communications*, **1996**, 218, 344-51	3.4	34
35	Molecular cloning and identification of murine caspase-8. *Journal of Molecular Biology*, **1998**, 284, 1017-26	6.5	33
34	Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. *Immunological Investigations*, **2006**, 35, 327-57	2.9	32
33	Part II: Vaccines for haematological malignant disorders. *Lancet Oncology, The*, **2004**, 5, 727-37	21.7	31
32	Induction of immunosuppressive functions and NF-B by FLIP in monocytes. *Nature Communications*, **2018**, 9, 5193	17.4	31
31	Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. *Immunological Investigations*, **2012**, 41, 722-37	2.9	29
30	Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. *European Journal of Immunology*, **2009**, 39, 56-66	6.1	23
29	In Brief: Myeloid-derived suppressor cells in cancer. *Journal of Pathology*, **2017**, 242, 7-9	9.4	21
28	Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo. *Current Protocols in Immunology*, **2019**, 124, e61	4	20
27	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. *Cancers*, **2020**, 12,	6.6	19
26	Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. *Journal of Nanobiotechnology*, **2020**, 18, 31	9.4	16
25	A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 molecules. *Journal of Immunology*, **2000**, 164, 4130-4	5.3	16
24	Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma. *OncoImmunology*, **2018**, 7, e1440931	7.2	12
23	CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes. *Biochemical and Biophysical Research Communications*, **1996**, 226, 769-76	3.4	12
22	Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients. *American Journal of Pathology*, **2013**, 183, 69-82	5.8	11

21	Technological platforms for microarray gene expression profiling. *Advances in Experimental Medicine and Biology*, **2007**, 593, 12-8	3.6	11
20	Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. *International Journal of Cancer*, **1996**, 65, 847-51	7.5	10
19	Inhibition of protein tyrosine phosphorylation prevents T-cell-mediated cytotoxicity. *Cellular Immunology*, **1994**, 159, 294-305	4.4	10
18	Synergistic effect of extracellular adenosine 5Rtriphosphate and tumor necrosis factor on DNA degradation. *Cellular Immunology*, **1993**, 152, 110-9	4.4	9
17	Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs). *Genomics Data*, **2014**, 2, 389-92		8
16	Role of anti-LFA-1 and anti-ICAM-1 combined MAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV). *International Journal of Cancer*, **1995**, 61, 355-62	7.5	7
15	Human miRNome profiling in colorectal cancer and liver metastasis development. *Genomics Data*, **2014**, 2, 184-8		6
14	Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. *Cancer Immunology, Immunotherapy*, **1992**, 35, 27-32	7.4	6
13	A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3 **1996**, 43, 377		6
12	Human MDSCs derived from the bone marrow maintain their functional ability but have a reduced frequency of induction in the elderly compared to pediatric donors. *Immunity and Ageing*, **2020**, 17, 27	9.7	4
11	Longitudinal evolution of the immune suppressive glioma microenvironment in different synchronous lesions during treatment. *Neuro-Oncology Advances*, **2020**, 2, vdz053	0.9	3
10	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation **2013**, 597-634		2
9	Role of iron metabolism in the immunosuppression mediated by myeloid cells in glioblastoma patients. *Annals of Oncology*, **2019**, 30, xi56	10.3	2
8	Cancer rejection by the immune system: Forcing the check-points of tumor immune escape. *Drug Discovery Today Disease Mechanisms*, **2005**, 2, 191-197		1
7	Therapeutical effect of 4Rdeoxy-4Riododoxorubicin-loaded LAK cells in mice bearing lung metastases. *Pharmacological Research*, **1992**, 26 Suppl 2, 124-5	10.2	1
6	Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy.. *Cancers*, **2021**, 13,	6.6	1
5	Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.. *Frontiers in Immunology*, **2021**, 12, 809826	8.4	0
4	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation **2007**, 369-399		

3	Inhibition of CTL-line lysis after gangliosides treatment. *Pharmacological Research*, **1992**, 26 Suppl 2, 190-1	10.2
2	Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma.. *Frontiers in Oncology*, **2022**, 12, 823812	5.3
1	Letter to the Editor Regarding "5-Aminolevulinic Acid False Positives in Cerebral Neuro-Oncology: Not All That Is Fluorescent Is Tumor. A Case-Based Update and Literature Review".. *World Neurosurgery*, **2022**, 161, 216-217	2.1